Ping Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ping Zhang has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Hua Han
Department of Biomedicine, Future Agriculture Institute, Northwest A&F University, Yangling, China
4 shared publications Li Wang
Fourth Military Medical University
3 shared publicationsLei Feng
Fourth Military Medical University
2 shared publicationsLiang Liang
State Key Laboratory of Cancer Biology, Department of Medical Genetics and Developmental Biology, Fourth Military Medical University, Xi'an 710038, China
2 shared publicationsChun-Mei Wang
Fourth Mil Med Univ, Dept Med Genet & Dev Biol, State Key Lab Canc Biol, Xian 710032, Peoples R China
1 shared publication- Da-Hai Hu
Department of Burns and Cutanous Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an 710038, China
1 shared publication
Latest Publications
- Open Access
- 31 March 2015
- Published by Springer Nature in Science China Life Sciences
- Vol. 58 (5) , 425-431
Endothelial cells-targeted soluble human Delta-like 4 suppresses both physiological and pathological ocular angiogenesis
Due to its essential roles in angiogenesis, Notch pathway has emerged as an attractive target for the treatment of pathologic angiogenesis. Although both activation and blockage of Notch signal can impede angiogenesis, activation of Notch signal may be more promising because it was shown that long-term Notch signal blockage resulted in vessel neoplasm. However, an in vivo deliverable Notch ligand with highly efficient Notch-activating capacity has not been developed. Among all the Notch ligands, Delta-like4 (Dll4) is specifically involved in angiogenesis. In this study, we generated a novel soluble Notch ligand hD4R, which consists of the Delta-Serrate-Lag-2 fragment of human Dll4 and an arginine-glycine-aspartate (RGD) motif targeting endothelial cells (ECs). We demonstrated that hD4R could bind to ECs through its RGD motif and effectively triggered Notch signaling in ECs. Further, we confirmed that hD4R could suppress angiogenesis in vitro as manifested by network formation assay and sprouting assay. More importantly, hD4R efficiently repressed neonatal retinal angiogenesis and laser-induced choroidal neovascularization (CNV) as well in vivo. In conclusion, we have developed an in vivo deliverable Notch ligand hD4R, which suppresses angiogenesis both in vitro and in vivo, thus providing a new approach to tackle excessive angiogenesis relevant disease such as CNV.
- 31 March 2015
- Published by Springer Nature in Science China Life Sciences
- Vol. 58 (5) , 425-431
Open AccessEndothelial cells-targeted soluble human Delta-like 4 suppresses both physiological and pathological ocular angiogenesis
Due to its essential roles in angiogenesis, Notch pathway has emerged as an attractive target for the treatment of pathologic angiogenesis. Although both activation and blockage of Notch signal can impede angiogenesis, activation of Notch signal may be more promising because it was shown that long-term Notch signal blockage resulted in vessel neoplasm. However, an in vivo deliverable Notch ligand with highly efficient Notch-activating capacity has not been developed. Among all the Notch ligands, Delta-like4 (Dll4) is specifically involved in angiogenesis. In this study, we generated a novel soluble Notch ligand hD4R, which consists of the Delta-Serrate-Lag-2 fragment of human Dll4 and an arginine-glycine-aspartate (RGD) motif targeting endothelial cells (ECs). We demonstrated that hD4R could bind to ECs through its RGD motif and effectively triggered Notch signaling in ECs. Further, we confirmed that hD4R could suppress angiogenesis in vitro as manifested by network formation assay and sprouting assay. More importantly, hD4R efficiently repressed neonatal retinal angiogenesis and laser-induced choroidal neovascularization (CNV) as well in vivo. In conclusion, we have developed an in vivo deliverable Notch ligand hD4R, which suppresses angiogenesis both in vitro and in vivo, thus providing a new approach to tackle excessive angiogenesis relevant disease such as CNV.
- 1 February 2014
- Published by Elsevier in Cellular Immunology
- Vol. 287 (2) , 129-135
Inhibition of Notch signaling leads to increased intracellular ROS by up-regulating Nox4 expression in primary HUVECs
- 1 February 2014
- Published by Elsevier in Cellular Immunology
- Vol. 287 (2) , 129-135
Inhibition of Notch signaling leads to increased intracellular ROS by up-regulating Nox4 expression in primary HUVECs
- 20 August 2009
- Published by Springer Nature in Molecular Biology Reports
- Vol. 37 (5) , 2301-2307
Expression, purification and characterization of the extracellular domain of human Flt3 ligand in Escherichia coli
Fms-like tyrosine kinase 3 ligand (Flt3 ligand, FL) is a cytokine that affects the growth, survival and/or differentiation of hematopoietic cells through the activation of specific tyrosine kinase receptors, and is potentially useful for in vitro HSC amplification. To express the extracellular domain of human Flt3 ligand (hFLext) in Escherichia coli, we cloned hFLext and constructed the recombinant expression vector pET32a-hFLext. hFLext was successfully expressed in E. coli as a Trx fusion protein (Trx-hFLext) under IPTG (isopropyl-β-d-thiogalactopyranoside) induction for 12 h at 30°C. The Trx-hFLext protein, expressed in inclusion bodies even at a low induction temperature, was successfully refolded and purified using dialysis and affinity chromatography. The purified hFLext was biologically active and could effectively stimulate the proliferation of mouse bone marrow nucleated cells revealed by cell proliferation assay and colony forming assay. In addition, in synergize with G-CSF and TPO, recombinant purified hFLext could stimulate ex vivo expansion of murine Lin−Sca-1+c-Kit+ cells. Therefore, using the E. coli expression system and an affinity chromatography system, we successfully expressed, refolded, and purified a biologically active Trx-hFLext protein which might be potentially useful for in vitro HSC amplification.
- 20 August 2009
- Published by Springer Nature in Molecular Biology Reports
- Vol. 37 (5) , 2301-2307
Expression, purification and characterization of the extracellular domain of human Flt3 ligand in Escherichia coli
Fms-like tyrosine kinase 3 ligand (Flt3 ligand, FL) is a cytokine that affects the growth, survival and/or differentiation of hematopoietic cells through the activation of specific tyrosine kinase receptors, and is potentially useful for in vitro HSC amplification. To express the extracellular domain of human Flt3 ligand (hFLext) in Escherichia coli, we cloned hFLext and constructed the recombinant expression vector pET32a-hFLext. hFLext was successfully expressed in E. coli as a Trx fusion protein (Trx-hFLext) under IPTG (isopropyl-β-d-thiogalactopyranoside) induction for 12 h at 30°C. The Trx-hFLext protein, expressed in inclusion bodies even at a low induction temperature, was successfully refolded and purified using dialysis and affinity chromatography. The purified hFLext was biologically active and could effectively stimulate the proliferation of mouse bone marrow nucleated cells revealed by cell proliferation assay and colony forming assay. In addition, in synergize with G-CSF and TPO, recombinant purified hFLext could stimulate ex vivo expansion of murine Lin−Sca-1+c-Kit+ cells. Therefore, using the E. coli expression system and an affinity chromatography system, we successfully expressed, refolded, and purified a biologically active Trx-hFLext protein which might be potentially useful for in vitro HSC amplification.